Skip to main content
Proceedings of the National Academy of Sciences of the United States of America logoLink to Proceedings of the National Academy of Sciences of the United States of America
. 2012 Dec 10;109(52):21516–21521. doi: 10.1073/pnas.1216988110

Loss of CDKL5 disrupts kinome profile and event-related potentials leading to autistic-like phenotypes in mice

I-Ting Judy Wang a, Megan Allen a, Darren Goffin a, Xinjian Zhu b,c, Andrew H Fairless d, Edward S Brodkin d, Steve J Siegel d, Eric D Marsh b,c, Julie A Blendy e, Zhaolan Zhou a,1
PMCID: PMC3535652  PMID: 23236174

Abstract

Mutations in the X-linked cyclin-dependent kinase-like 5 (CDKL5) gene have been identified in neurodevelopmental disorders including atypical Rett syndrome (RTT), autism spectrum disorders (ASDs), and early infantile epileptic encephalopathy. The biological function of CDKL5 and its role in the etiology of these disorders, however, remain unclear. Here we report the development of a unique knockout mouse model of CDKL5-related disorders and demonstrate that mice lacking CDKL5 show autistic-like deficits in social interaction, as well as impairments in motor control and fear memory. Neurophysiological recordings reveal alterations in event-related potentials (ERPs) similar to those observed in RTT and ASDs. Moreover, kinome profiling uncovers disruption of multiple signal transduction pathways, including the AKT-mammalian target of rapamycin (mTOR) cascade, upon Cdkl5 loss-of-function. These data demonstrate that CDKL5 regulates signal transduction pathways and mediates autistic-like phenotypes and together establish a causal role for Cdkl5 loss-of-function in neurodevelopmental disorders.


Cyclin-dependent kinase-like 5 (CDKL5) is an X-linked gene associated with early infantile epileptic encephalopathy 2 (EIEE2) (1), atypical Rett syndrome (RTT) (2), and autism spectrum disorders (ASDs) (3, 4). Patients with CDKL5 mutations display a heterogenous array of clinical phenotypes, the most prominent of which include early-onset seizures, intellectual disability, and autistic features (5).

CDKL5 is a serine/threonine (S/T) kinase that is highly expressed in the brain (6). In vitro studies have demonstrated that CDKL5 may mediate the phosphorylation of methyl-CpG binding protein 2 (MeCP2) (7), DNA methyltransferase 1 (DNMT1) (8), and netrin-G1 ligand (NGL-1) (9). RNAi-mediated knockdown studies show that CDKL5 can regulate neuronal outgrowth and synapse stability (9, 10). Despite these proposed functions, the exact role of CDKL5 in the phosphorylation of MeCP2 (7, 11) and in dendritic outgrowth (9, 10) remains unclear, and thus requires further investigation. The limited understanding of CDKL5 function and its associated signal transduction pathways has hindered the development of therapeutics for CDKL5-related disorders. Current treatments focus on managing symptoms and reducing seizure frequency, but have limited effectiveness (12).

To investigate the function of CDKL5 in a disease model and identify potential avenues of therapeutic intervention, we developed a Cdkl5 knockout mouse. We found that mice lacking CDKL5 show autistic-like behavioral abnormalities, deficits in neural circuit communication, and alterations in multiple signal transduction pathways. We establish a causal link between Cdkl5 loss-of-function and disease-related phenotypes and identify the AKT-mammalian target of rapamycin (mTOR) pathway as a unique candidate for targeted therapeutic intervention of CDKL5-related disorders.

Results

Generation of Cdkl5 Knockout Mice.

To investigate the pathophysiology underlying CDKL5-related disorders, we generated a Cdkl5 knockout mouse that models a splice site mutation found in a CDKL5 patient. This mutation results in the skipping of human CDKL5 exon 7, generating a premature termination codon and causing an early truncation of CDKL5 in its N-terminal kinase domain, thereby disrupting kinase activity (13). To mimic the effects of this splice site mutation, we deleted mouse Cdkl5 exon 6 through homologous-mediated recombination in ES cells (Fig. 1A). Deletion of Cdkl5 exon 6 leads to a similar shift in the reading frame and premature truncation within the N-terminal kinase domain (Fig. 1 A and B). The absence of Cdkl5 exon 6 at the DNA and mRNA levels was verified by PCR of genomic DNA and sequencing of cDNA prepared from Cdkl5 knockout mouse brains (Fig. 1 C and D). Loss of full-length CDKL5 protein was verified by Western blot (Fig. 1E). A truncated CDKL5 protein product in neurons isolated from Cdkl5 knockout mice has not been detected by antibodies raised against CDKL5 N- or C-terminal domains, likely due to nonsense stop codon mediated mRNA decay (Fig. S1A). In addition, female heterozygotes show decreased CDKL5 protein expression relative to WT female mice, as expected from X-linked mosaicism (Fig. S1B). Thus, deletion of Cdkl5 exon 6 likely represents a loss-of-function mutation. Experimental mice have been backcrossed onto the C57BL/6 background for at least six generations. Male mice lacking CDKL5 (Cdkl5–/y) and female heterozygotes (Cdkl5−/+) are viable, fertile, and display normal appearance, growth, and overall brain morphology (Fig. S1 C and D).

Fig. 1.

Fig. 1.

Generation of Cdkl5 knockout mice. (A) Targeting strategy. Three loxP sites and a neomycin positive selection cassette (Neo) were inserted surrounding the genomic locus of Cdkl5 exon 6 via homologous recombination. Upon Cre-directed recombination, both the Neo cassette and exon 6 were excised. (B) Schematic of CDKL5 protein in WT and knockout. The excision of exon 6 causes a reading frame shift, resulting in a TAA stop codon in the 5′ end of exon 7, leading to truncation of CDKL5 in its kinase domain (red). (C) PCR of genomic DNA using primers flanking exon 6. A 300-bp PCR product in Cdkl5–/y mice indicates the absence of Cdkl5 exon 6. (D) Sequencing of cDNA generated from Cdkl5 mRNA. Excision of exon 6 in Cdkl5–/y mice causes the reading frame, highlighted in black, to be shifted in Cdkl5–/y mice, resulting in a premature stop codon (TAA, circled in red) at the 5′ end of exon 7. (E) Western blot probed with an antibody directed against CDKL5. Full-length CDKL5 protein is absent in Cdkl5–/y mice.

Hyperactivity, Motor Impairments, and Decreased Anxiety in Cdkl5–/y Mice.

Given the clinical relevance of CDKL5-related disorders in males (14, 15) and the confounding effects of mosaic CDKL5 expression in females from random X-chromosome inactivation, we characterized the behavioral profile of Cdkl5 knockouts in male (Cdkl5–/y) mice, compared with wild-type male littermates (WT, Cdkl5+/y). We found that Cdkl5–/y mice exhibit motor and anxiety impairments similar to those observed in other ASD and RTT mouse models (2, 1619). In a locomotor assay within a home cage-like environment, Cdkl5–/y mice demonstrated significantly higher motor activity relative to WT littermate controls (Fig. 2A). Similar hyperactivity was also observed in the zero maze test and social approach test (Fig. S2 A and B).

Fig. 2.

Fig. 2.

Behavioral phenotyping of Cdkl5–/y mice. (A) Sixty-minute locomotor assay, measured by infrared beam breaks in a home cage-like environment. Cdkl5–/y mice (n = 19) display increased activity relative to wild type (WT, Cdkl5+/y) littermates (n = 15). Two-way repeated measures (RM) ANOVA, P < 0.0001 (interaction). (B) Rotarod assay, measuring latency to fall from an accelerating rotating rod. Testing was performed five trials per day for 5 consecutive days. Latency to fall is decreased in Cdkl5–/y mice (n = 18) relative to WT littermates (n = 15), indicating impaired motor coordination in Cdkl5–/y mice. Two-way ANOVA, P < 0.01 (main effect of genotype). (C) Cdkl5–/y mice (n = 14) spend more time in the open arms and less time in the closed arms of a zeromaze assay relative to WT littermates (n = 12), showing decreased anxiety. *P < 0.05, unpaired two-tailed Student t test. (D) Three-chambered social approach assay. Cdkl5–/y mice (n = 17) spend less time in a social chamber containing a stimulus mouse (S) and more time in a nonsocial chamber containing a novel object (NS) relative to WT mice (n = 15). C, center. Two-way ANOVA with Bonferroni correction, P < 0.0001 (interaction); **P < 0.01, ***P < 0.001. (E) Cdkl5–/y mice (n = 17) spend significantly more time sniffing a novel object (NS) and trend toward less time sniffing a stimulus mouse (S) relative to WT mice (n = 15). Two-way ANOVA with Bonferroni correction, P < 0.01 (interaction); *P < 0.05. (F) Cdkl5–/y mice (n = 17) spend less time directly interacting with a freely moving stimulus mouse compared with WT littermates (n = 15). ***P < 0.001, unpaired two-tailed Student t test. (G) Cdkl5–/y mice (n = 12) show impaired nesting behavior relative to WT littermates (n = 11) at 4–5 postnatal weeks. ***P < 0.001, unpaired two-tailed Student t test. (H) Fear conditioning paradigm, measuring time spent immobile. While Cdkl5–/y mice (n = 14) freeze in response to a mild footshock similarly to WT littermates (postshock), they show decreased freezing upon return to the testing chamber (context) and upon hearing the testing tone (cue) relative to WT littermates (n = 14), demonstrating impaired learning and memory in Cdkl5–/y mice. Two-way ANOVA with Bonferroni correction, P < 0.01 (interaction); *P < 0.05. All data are presented as mean ± SEM.

On an accelerating rotarod assay, the latency to fall in Cdkl5–/y mice increased across trials similarly to that of WT mice, but was consistently lower than that of WT (Fig. 2B), indicating that Cdkl5–/y mice have comparable motor learning but impaired motor coordination relative to their WT littermates. Cdkl5–/y mice also showed decreased anxiety-related behavior in a zero maze test similar to that of Mecp2 mouse models of RTT, spending more time in open areas and less time in the closed areas relative to WT littermates (Fig. 2C). In addition, we have observed hindlimb and forelimb clasping in Cdkl5–/y mice (Fig. S2C), a phenotype also exhibited in Mecp2 mouse models (1922). These data demonstrate that Cdkl5–/y mice exhibit hyperactivity, impaired motor control, and decreased anxiety, phenotypes that have also been observed in ASD and RTT patients (2, 5, 23).

Autistic-Like Social Behavior in Cdkl5–/y Mice.

Given that deficits in social interaction are a hallmark feature of ASDs and are prevalent in patients with CDKL5 mutations (5, 24), we next examined sociability using a three-chambered social approach test and found that mice lacking CDKL5 demonstrate profound impairment in social interaction. During the initial habituation phase, both WT and Cdkl5–/y mice explored both chambers equally, demonstrating no initial chamber preference (Fig. S2D). However, upon introduction of a novel object into one chamber (nonsocial chamber, NS) and a novel gonadectomized male A/J stimulus mouse into the other chamber (social chamber, S), Cdkl5–/y mice showed reduced social preference relative to WT mice, spending less time in the social chamber and more time in the nonsocial chamber relative to WT mice (Fig. 2D). In addition, Cdkl5–/y mice spent more time sniffing the novel object and a trend toward less time sniffing the novel stimulus mouse relative to WT mice (Fig. 2E). Furthermore, when barriers were removed to allow freely mobile direct interaction, Cdkl5–/y mice spent significantly less time interacting (sniffing, allogrooming) with the stimulus mouse compared with WT littermates (Fig. 2F).

Cdkl5–/y mice also displayed impaired nesting, a phenotype related to home-cage social behavior that has been observed in ASD and RTT mouse models (17, 25, 26) (Fig. 2G). Importantly, we found no olfaction impairments in either genotype (Fig. S2E), suggesting that the social deficits in Cdkl5–/y mice are not the secondary consequence of an inability to discriminate between social and neutral odors. Together, these data demonstrate that Cdkl5–/y mice have ASD-like deficits in social behavior.

Impaired Learning and Memory in Cdkl5–/y Mice.

Because intellectual disability is a common clinical phenotype among CDKL5 patients (12), we also assessed learning and memory in Cdkl5 knockout mice using context- and cue-dependent fear conditioning. During the acquisition phase, both WT and Cdkl5–/y mice showed similar exploratory behavior before the foot shock and similar freezing behavior immediately following the foot shock (Fig. 2H). When reexposed to the shock box or paired tone 24 h later, Cdkl5–/y mice froze significantly less than WT littermates, indicating impaired contextual and cued fear memory (Fig. 2H). Taken together, these behavioral studies demonstrate that mice lacking CDKL5 have deficits in motor function, social behavior, and learning and memory.

Normal EEG Patterns and Absence of Spontaneous Seizures in Cdkl5–/y Mice.

Given the prevalence of intractable seizures in patients with CDKL5 mutations (12), we next examined the occurrence of spontaneous seizures in Cdkl5 knockout mice through video-EEG recordings. We did not, however, observe any spontaneous seizures in Cdkl5–/y mice recorded for at least 72 h, with some mice recorded for as long as 240 h. Consistent with this finding, the basal EEG patterns and power distribution across different oscillation frequencies in Cdkl5–/y mice were similar to that of WT littermates (Fig. S3 A and B). Despite the large degree of homology between the murine and human CDKL5 protein, the absence of spontaneous seizures observed in our Cdkl5–/y mice may reflect a distinct function or modification of CDKL5 in humans that is absent in lower organisms. Moreover, the C57BL/6 genetic background is known to confer increased seizure resistance (27), thus potentially occluding spontaneous seizures in our Cdkl5–/y mice.

Event-Related Potential Deficits in Cdkl5–/y Mice.

The absence of spontaneous seizures in Cdkl5–/y mice, however, allowed us to examine neural circuit deficits that are mediated by Cdkl5 loss-of-function rather than the secondary consequence of seizures. Sensory information processing measured as an event-related potential (ERP) has recently been proposed as a biomarker to monitor neural circuit function in ASD and RTT animal models (19, 28, 29). We therefore recorded auditory-evoked ERPs in adult WT and Cdkl5–/y mice, as these ERP assessments can be performed on nonanesthetized, freely mobile mice and are not confounded by the motor and cognitive deficits observed in Cdkl5–/y mice. Compared with the characteristic amplitude and latency of the P1 (positive), N1 (negative), and P2 polarity peaks in WT mice, Cdkl5–/y mice display an aberrant ERP waveform (Fig. 3A). We observed a significant decrease in the amplitude of the N1 and P2 peaks and a significant increase in latency of the P2 peak (Fig. 3 AC). Importantly, auditory brainstem recordings detected no hearing impairments in either genotype. As the amplitude and latency of these polarity peaks are believed to reflect the strength and timing of cognitive processes, these data indicate that Cdkl5 loss-of-function disrupts neural circuit communication. Notably, patients with ASD and RTT have alterations in both amplitude and latencies of ERPs (30, 31).

Fig. 3.

Fig. 3.

Cdkl5–/y mice display impaired ERP waveform and decreased event-related power and phase locking. (A) Grand-average ERP waveform following presentation of 250 85-dB white noise stimuli with 4-s interstimulus intervals in adult WT (Cdkl5+/y) (n = 9) and Cdkl5–/y mice (n = 9). Traces represent mean amplitude ± SEM. Characteristic polarity peaks P1, N1, and P2 in WT are labeled. [Scale bar, 100 ms (horizontal) and 20 mV (vertical).] (B) Amplitude and (C) latency of ERP peaks. Bars represent mean ± SEM; **P < 0.01, *P < 0.05, unpaired two-tailed Student t test with Bonferroni correction. (D) Time–frequency plots showing changes in event-related power following an 85-dB auditory stimulus. Color represents mean power, where warmer colors correspond to increased power and cooler colors correspond to decreased power relative to prestimulus baseline. (E) Changes in event-related mean power averaged across δ (2–4 Hz), θ (4–8 Hz), α (8–12 Hz), β (12–30 Hz), γlow (30–50 Hz), and γhigh (70–140 Hz) oscillation frequencies. (Scale bars, length of a single δ oscillation cycle.) Insets show power traces on an expanded timescale, denoted by the length of a single oscillation cycle. Traces represent mean amplitude ± SEM. (F) Time–frequency plots showing changes in event-related phase-locking factor (PLF) following an 85-dB auditory stimulus. Color represents PLF, where warmer colors correspond to a higher PLF or lower circular variance in EEG phase across trials. (G) Changes in event-related PLF averaged across frequencies described above. (Scale bars, length of a single oscillation cycle.) Insets show traces on an expanded timescale. Traces represent mean PLF ± SEM.

Disruption of Low-Frequency Event-Related Neuronal Oscillations in Cdkl5–/y Mice.

Circuit communication is composed of neuronal oscillations over a range of frequencies. We therefore also performed time–frequency analysis of the ERPs to examine frequency-specific changes in instantaneous power and phase locking in response to the auditory stimuli. Cdkl5–/y mice demonstrated reduced oscillatory strength specifically at low frequencies, showing attenuated event-related depression in the low-frequency delta (δ, 2–4 Hz), theta (θ, 4–8 Hz), and alpha (α, 8–12 Hz) oscillations, but no difference in the high-frequency beta (β, 12–30 Hz), low gamma (γlow, 30–50 Hz), and high gamma (γhigh, 70–140 Hz) oscillations relative to WT controls (Fig. 3 D and E and Fig. S4A). Similarly, event-related phase locking, which reflects the reliability and sensitivity of circuit communication, and is measured by the phase-locking factor (PLF), were also significantly decreased in Cdkl5–/y mice exclusively in the low-frequency δ, θ, and α oscillations relative to WT littermates (Fig. 3 F and G and Fig. S4B). Given that oscillatory activity in low-frequency ranges is associated with long-range neuronal circuit communication and high-frequency oscillations with local circuit communication (28, 32), our data suggest that ERP deficits in Cdkl5–/y mice may be mediated by impairments in long-range communication. Notably, EEG studies in ASD children have reported specific deficits in low-frequency δ, θ, and α oscillations (33, 34), indicating that similar neuronal network defects exist in Cdkl5–/y mice and ASD patients.

Disrupted Kinome Profile in Cdkl5–/y Mice.

Given the highly conserved S/T kinase domain in CDKL5 (Fig. 1B), we reasoned that Cdkl5 loss-of-function may disrupt phosphorylation of CDKL5 kinase substrates and related signaling pathways, thereby mediating deficits in neuronal network communication and autistic-like behaviors in Cdkl5–/y mice. Previous studies have reported that CDKL5 may mediate the phosphorylation of MeCP2 (7), DNMT1 (8), and NGL-1 (9) in vitro. The CDKL5 substrates in vivo, however, remain unknown. Therefore, to investigate the signaling networks affected by the absence of CDKL5 in vivo in an unbiased manner, we surveyed the S/T kinome profile in Cdkl5 knockout mice, assessing the consequence of Cdkl5 loss-of-function on overall S/T phosphorylation events. Because CDKL5 expression is enriched in the forebrain regions of the striatum, cortex, and hippocampus (Fig. S5), we probed brain-region–specific lysate from WT and Cdkl5–/y mice with multiple antibodies developed against a large set of well-characterized S/T phosphorylation motifs (35, 36). We identified a range of phosphorylation profiles affected by the loss of CDKL5 (Fig. 4A). Of these, the phosphorylation of adenosine monophosphate-activated protein kinase (AMPK), protein kinase A (PKA), and AKT substrates were strongly decreased in Cdkl5–/y mice (Fig. 4 B and C and Fig. S6), whereas other phosphorylation profiles were moderately or mildly affected [e.g., mitogen-activated protein kinase (MAPK), ataxia-telangiectasia mutated/ataxia-telangiectasia and Rad3-related (ATM/ATR), and cyclin-dependent kinase (CDK) substrates] (Fig. 4A and Figs. S7 and S8). Importantly, changes in phosphorylation profiles were clearly evident in forebrain regions including the striatum, somatosensory cortex, and hippocampus where CDKL5 is enriched and less pronounced in hindbrain regions including the brainstem where CDKL5 expression is low (Fig. 4 B and C and Figs. S5S7), supporting a role of CDKL5 in the regulation of these pathways.

Fig. 4.

Fig. 4.

Altered kinome profile and disrupted AKT–mTOR signaling in Cdkl5–/y mice. (A) Summary of changes in kinome profile in Cdkl5–/y mice relative to WT littermates. Whole cell lysates from the cerebellum, striatum, somatosensory cortex, olfactory bulb, hippocampus, and brainstem of WT (n = 7) and Cdkl5–/y mice (n = 8) were probed with antibodies raised against different phosphorylation motifs representing known S/T kinases. Western blots were quantified using the Odyssey Infrared Imaging system and fold change in phosphorylation level between Cdkl5–/y and WT mice across the six brain regions are expressed as log2 (phosphorylation level in WT over phosphorylation level in Cdkl5–/y). Color scheme indicates relative degree of phosphorylation reduction in Cdkl5–/y mice: purple, strong; blue, moderate; and green, mild. (B and C) Whole cell lysate probed with an antibody specific for an RXRXX(s/t) phosphorylation motif representing AKT kinase substrates (B) and an antibody specific for an LXRXX(s/t) phosphorylation motif representing AMPK kinase substrates (C) shows a marked decrease in phosphorylation profiles in Cdkl5–/y mice (KO) relative to WT littermates in the striatum, somatosensory cortex (ss cortex), and hippocampus, but moderate decrease in the brainstem, consistent with regions of high and low CDKL5 expression, respectively. (D) AKT S473 and mTOR S2448 phosphorylation is reduced in whole brain lysate from Cdkl5–/y mice (KO) related to WT mice, whereas total levels of AKT and mTOR are unchanged. (E and F) Quantification of reduced AKT S473 (E) and mTOR S2448 (F) phosphorylation in Cdkl5–/y mice. Phosphorylated protein levels are normalized to GAPDH loading control and expressed relative to WT levels. *P < 0.05, unpaired two-tailed Student t test with Bonferroni correction. (G and H) Quantification of total AKT (G) and mTOR (H) in WT and Cdkl5–/y mice. Protein levels are normalized to GAPDH loading control and expressed relative to WT levels. NS, not significant; unpaired two-tailed Student t test.

Disruption of AKT–mTOR Signaling in Cdkl5–/y Mice.

The changes in the AMPK, AKT, PKC, and MAPK phosphorylation profiles suggested a convergence on the downstream signaling of phosphatase and tensin homolog (PTEN). Notably, mutations and dysfunction of components of this pathway, including PTEN, AKT, tuberous sclerosis complex (TSC), and mTOR, have been linked to ASDs, RTT, and epileptic encephalopathies (18, 37, 38). To validate the disruption of AKT–mTOR signaling in Cdkl5–/y mice, we measured the phosphorylation of AKT S473 and mTOR S2448 and found decreased phosphorylation of both AKT and mTOR in Cdkl5–/y mice, with no concomitant alteration in total AKT or mTOR protein levels (Fig. 4 DH). As phosphorylation of these residues promote AKT activation and mTOR complex 1 (mTORC1) assembly, respectively (39, 40), this finding is consistent with the overall decreased phosphorylation of AKT substrates in Cdkl5–/y mice (Fig. 4C and Fig. S6 B and D) and likely reflect decreased AKT and mTORC1 activity upon Cdkl5 loss-of-function. Together, we conclude that multiple signal transduction pathways, including the AKT–mTOR cascade, are disrupted upon the absence of CDKL5.

Discussion

In this study, we show that loss of CDKL5 in mice results in autistic-like behavioral deficits, impairment in neuronal communication, and disruptions in serine/threonine phosphorylation profiles. We establish a unique causal relationship between Cdkl5 loss-of-function and disease-related phenotypes.

Core characteristics of CDKL5-related disorders include early-onset seizures, severe intellectual disability, and autistic-like features. In our behavioral analysis, we found that our Cdkl5 knockout mice mirror the latter features, but not early-onset seizures. Cdkl5–/y mice display hyperactivity, motor defects, reduced anxiety, decreased sociability, and impaired learning and memory. These phenotypes have been described in other ASD and RTT mouse models (2, 16, 17, 19, 26) and may mimic the absence of hand skills, intellectual disability, hyperactivity, and poor response to social interactions that have been described in CDKL5 patients (12, 41).

While video-EEG monitoring revealed an absence of spontaneous seizures in Cdkl5–/y mice, ERP analysis showed attenuated and delayed ERP polarity peaks suggestive of impaired neuronal connectivity, which is consistent with findings in ASD and RTT patients (30, 31) and animal models (19, 28, 29). Importantly, these behavioral and electrophysiological impairments are unlikely the secondary effects of an epileptic neuronal network, suggesting they are consequences of Cdkl5 loss-of-function.

Time–frequency analysis of ERPs identified a specific deficit in event-related δ, θ, and α low-frequency neuronal oscillations in Cdkl5–/y mice. Interestingly, abnormalities in low-frequency neuronal oscillations have been reported in ASD children (33, 34). In addition, impairments in α and γ oscillations have also been described in ASDs, as α is believed to function in attention suppression of distracting stimuli and γ in feature binding (42, 43). Alpha oscillations have also been proposed to mediate long-distance coordination of γ oscillations (44). Thus, our data suggest that the oscillatory network of Cdkl5–/y mice may resemble that of ASD, where γ oscillations themselves are not affected, but rather, their α-mediated long-distance coordination. Moreover, as θ oscillations are proposed to support encoding and retrieval of memory (45, 46), the impairment in event-related power and PLF at the θ frequency are consistent with the learning and memory deficits in Cdkl5–/y mice and the prominent intellectual disability observed in patients with CDKL5-related disorders.

Lastly, our S/T kinome study revealed that many signal transduction pathways are disrupted in Cdkl5 knockout mice. Of these, many pathway components, including the AKT–mTOR pathway, have been implicated in the etiology of ASDs (18, 47). Given that mTOR is a known regulator of cell growth, proliferation, motility, and neural plasticity (48), one consequence of reduced AKT–mTOR activity in the absence of CDKL5 is the disruption of neuronal development. Accordingly, RNAi-mediated knockdown of CDKL5 results in impaired dendritic outgrowth, neuronal migration (10), and spine maturation (9). Together, these data suggest a mechanism by which CDKL5 regulates AKT–mTOR-mediated cellular development, thus implicating the AKT–mTOR pathway as a potential therapeutic target for treatment of patients with CDKL5-related disorders.

In addition to the AKT–mTOR pathway, we found that the phosphorylation profiles of kinases involved in synaptic plasticity, including PKA, PKC, and protein kinase D (PKD), as well as kinases involved in cellular metabolism, including AMPK, ATM/ATR, and casein kinase (CK) (Figs. S6 and S7) were also decreased in Cdkl5–/y mice. Although many of these signaling changes may be indirect effects of Cdkl5 loss-of-function, these data suggest that CDKL5 plays a critical role in coordinating multiple signaling cascades. Indeed, CDKL5 has been shown to regulate brain-derived neurotropic factor (BDNF)-induced activation of Rho family small GTPase Rac1 (10) and deficits in synaptic plasticity are commonly described in ASDs (17, 49). Consistent with these cellular functions, we found that CDKL5 is predominantly localized in the cytoplasm (Fig. S9). Notably, links between these signaling pathways have been previously described, as CK regulates glutamatergic synaptic transmission (50), ATM mediates AKT S473 phosphorylation (51), and mutations in ATM cause the neurodegenerative movement disorder ataxis telegiectasia (52). It is possible, therefore, that CDKL5 may serve to mediate cross-talk between these signaling pathways.

Our data support an increasing awareness that CDKL5-related disorders are an independent clinical entity with an independent pathogenic mechanism, rather than a subclass of RTT. Strikingly, only less than one-quarter of individuals with CDKL5 mutations meet the criteria for the early-onset seizure variant of RTT (53, 54). Its genetic link to neurodevelopmental disorders and recent identification as an ASD hotspot for balanced chromosomal rearrangements (4) highlight the need to characterize CDKL5 biological function, understand the mechanisms underlying CDKL5-related disorders, and identify effective therapies targeted toward slowing or reversing disease progression. Our study, therefore, provides a framework and an animal model for mechanistic and therapeutic studies of CDKL5-related disorders.

Materials and Methods

All behavioral, EEG, ERP, and kinome studies were performed on adult mice 9–12 wk of age backcrossed onto a C57BL/6 background for at least six generations, unless otherwise indicated. For ERP studies, tripolar electrodes were implanted and ERP traces were obtained by averaging single trial epochs of 250 white-noise stimuli of 10-ms duration, 85-dB sound pressure, and 4-s interstimulus intervals.

Data are reported as mean ± SEM, and statistical analysis was performed using GraphPad Prism software.

Other materials and methods are presented in SI Materials and Methods.

Supplementary Material

Supporting Information

Acknowledgments

We thank members of the Z.Z. laboratory for critical readings of the manuscript; Dr. Michael E. Greenberg and the Intellectual and Developmental Disability Research Center (M. Thompson, Y. Zhou, and H. Ye; P30 HD18655) at the Children’s Hospital Boston for assistance in the generation of transgenic mice; Brenda Porter at the Children’s Hospital of Philadelphia for assistance in EEG recordings; and J. Silva, C. Farnsworth, and X. Jia at Cell Signaling Technologies for assistance with kinome profiling. This work was supported by a startup fund from the Department of Genetics, University of Pennsylvania Perelman School of Medicine (to Z.Z.) and National Institutes of Health Grants NS058391 (to Z.Z.), MH080718 (to E.S.B.), and MH017168 (to A.H.F.). Z.Z. is a Pew Scholar in Biomedical Science.

Footnotes

The authors declare no conflict of interest.

*This Direct Submission article had a prearranged editor.

This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10.1073/pnas.1216988110/-/DCSupplemental.

References

  • 1.Nabbout R, Dulac O. Epilepsy. Genetics of early-onset epilepsy with encephalopathy. Nat Rev Neurol. 2011;8(3):129–130. doi: 10.1038/nrneurol.2012.12. [DOI] [PubMed] [Google Scholar]
  • 2.Chahrour M, Zoghbi HY. The story of Rett syndrome: From clinic to neurobiology. Neuron. 2007;56(3):422–437. doi: 10.1016/j.neuron.2007.10.001. [DOI] [PubMed] [Google Scholar]
  • 3.Sakai Y, et al. Protein interactome reveals converging molecular pathways among autism disorders. Sci Transl Med. 2011;3(86):86ra49. doi: 10.1126/scitranslmed.3002166. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Talkowski ME, et al. Sequencing chromosomal abnormalities reveals neurodevelopmental loci that confer risk across diagnostic boundaries. Cell. 2012;149(3):525–537. doi: 10.1016/j.cell.2012.03.028. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Bahi-Buisson N, et al. Key clinical features to identify girls with CDKL5 mutations. Brain. 2008;131(Pt 10):2647–2661. doi: 10.1093/brain/awn197. [DOI] [PubMed] [Google Scholar]
  • 6.Kilstrup-Nielsen C, et al. What we know and would like to know about CDKL5 and its involvement in epileptic encephalopathy. Neural Plast. 2012;2012:728267. doi: 10.1155/2012/728267. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Mari F, et al. CDKL5 belongs to the same molecular pathway of MeCP2 and it is responsible for the early-onset seizure variant of Rett syndrome. Hum Mol Genet. 2005;14(14):1935–1946. doi: 10.1093/hmg/ddi198. [DOI] [PubMed] [Google Scholar]
  • 8.Kameshita I, et al. Cyclin-dependent kinase-like 5 binds and phosphorylates DNA methyltransferase 1. Biochem Biophys Res Commun. 2008;377(4):1162–1167. doi: 10.1016/j.bbrc.2008.10.113. [DOI] [PubMed] [Google Scholar]
  • 9.Ricciardi S, et al. CDKL5 ensures excitatory synapse stability by reinforcing NGL-1-PSD95 interaction in the postsynaptic compartment and is impaired in patient iPSC-derived neurons. Nat Cell Biol. 2012;14(9):911–923. doi: 10.1038/ncb2566. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Chen Q, et al. CDKL5, a protein associated with Rett syndrome, regulates neuronal morphogenesis via Rac1 signaling. J Neurosci. 2010;30(38):12777–12786. doi: 10.1523/JNEUROSCI.1102-10.2010. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Lin C, Franco B, Rosner MR. CDKL5/Stk9 kinase inactivation is associated with neuronal developmental disorders. Hum Mol Genet. 2005;14(24):3775–3786. doi: 10.1093/hmg/ddi391. [DOI] [PubMed] [Google Scholar]
  • 12.Bahi-Buisson N, Bienvenu T. CDKL5-related disorders: From clinical description to molecular genetics. Mol Syndromol. 2012;2(3-5):137–152. doi: 10.1159/000331333. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Archer HL, et al. CDKL5 mutations cause infantile spasms, early onset seizures, and severe mental retardation in female patients. J Med Genet. 2006;43(9):729–734. doi: 10.1136/jmg.2006.041467. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Liang J-S, et al. CDKL5 alterations lead to early epileptic encephalopathy in both genders. Epilepsia. 2011;52(10):1835–1842. doi: 10.1111/j.1528-1167.2011.03174.x. [DOI] [PubMed] [Google Scholar]
  • 15.Moseley BD, Dhamija R, Wirrell EC, Nickels KC. Historic, clinical, and prognostic features of epileptic encephalopathies caused by CDKL5 mutations. Pediatr Neurol. 2012;46(2):101–105. doi: 10.1016/j.pediatrneurol.2011.11.007. [DOI] [PubMed] [Google Scholar]
  • 16.Schmeisser MJ, et al. Autistic-like behaviours and hyperactivity in mice lacking ProSAP1/Shank2. Nature. 2012;486(7402):256–260. doi: 10.1038/nature11015. [DOI] [PubMed] [Google Scholar]
  • 17.Won H, et al. Autistic-like social behaviour in Shank2-mutant mice improved by restoring NMDA receptor function. Nature. 2012;486(7402):261–265. doi: 10.1038/nature11208. [DOI] [PubMed] [Google Scholar]
  • 18.Tsai PT, et al. Autistic-like behaviour and cerebellar dysfunction in Purkinje cell Tsc1 mutant mice. Nature. 2012;488(7413):647–651. doi: 10.1038/nature11310. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Goffin D, et al. Rett syndrome mutation MeCP2 T158A disrupts DNA binding, protein stability and ERP responses. Nat Neurosci. 2012;15(2):274–283. doi: 10.1038/nn.2997. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Guy J, Hendrich B, Holmes M, Martin JE, Bird A. A mouse Mecp2-null mutation causes neurological symptoms that mimic Rett syndrome. Nat Genet. 2001;27(3):322–326. doi: 10.1038/85899. [DOI] [PubMed] [Google Scholar]
  • 21.Shahbazian M, et al. Mice with truncated MeCP2 recapitulate many Rett syndrome features and display hyperacetylation of histone H3. Neuron. 2002;35(2):243–254. doi: 10.1016/s0896-6273(02)00768-7. [DOI] [PubMed] [Google Scholar]
  • 22.Chao H-T, et al. Dysfunction in GABA signalling mediates autism-like stereotypies and Rett syndrome phenotypes. Nature. 2010;468(7321):263–269. doi: 10.1038/nature09582. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Geschwind DH. Advances in autism. Annu Rev Med. 2009;60:367–380. doi: 10.1146/annurev.med.60.053107.121225. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Abrahams BS, Geschwind DH. Advances in autism genetics: On the threshold of a new neurobiology. Nat Rev Genet. 2008;9(5):341–355. doi: 10.1038/nrg2346. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Samaco RC, et al. A partial loss of function allele of methyl-CpG-binding protein 2 predicts a human neurodevelopmental syndrome. Hum Mol Genet. 2008;17(12):1718–1727. doi: 10.1093/hmg/ddn062. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Peñagarikano O, et al. Absence of CNTNAP2 leads to epilepsy, neuronal migration abnormalities, and core autism-related deficits. Cell. 2011;147(1):235–246. doi: 10.1016/j.cell.2011.08.040. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.McLin JP, Steward O. Comparison of seizure phenotype and neurodegeneration induced by systemic kainic acid in inbred, outbred, and hybrid mouse strains. Eur J Neurosci. 2006;24(8):2191–2202. doi: 10.1111/j.1460-9568.2006.05111.x. [DOI] [PubMed] [Google Scholar]
  • 28.Gandal MJ, et al. Validating γ oscillations and delayed auditory responses as translational biomarkers of autism. Biol Psychiatry. 2010;68(12):1100–1106. doi: 10.1016/j.biopsych.2010.09.031. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Liao W, Gandal MJ, Ehrlichman RS, Siegel SJ, Carlson GC. MeCP2+/- mouse model of RTT reproduces auditory phenotypes associated with Rett syndrome and replicate select EEG endophenotypes of autism spectrum disorder. Neurobiol Dis. 2012;46(1):88–92. doi: 10.1016/j.nbd.2011.12.048. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Stauder JEA, Smeets EEJ, van Mil SGM, Curfs LGM. The development of visual- and auditory processing in Rett syndrome: An ERP study. Brain Dev. 2006;28(8):487–494. doi: 10.1016/j.braindev.2006.02.011. [DOI] [PubMed] [Google Scholar]
  • 31.Roberts TPL, et al. MEG detection of delayed auditory evoked responses in autism spectrum disorders: Towards an imaging biomarker for autism. Autism Res. 2010;3(1):8–18. doi: 10.1002/aur.111. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Winterer G, et al. Schizophrenia: Reduced signal-to-noise ratio and impaired phase-locking during information processing. Clin Neurophysiol. 2000;111(5):837–849. doi: 10.1016/s1388-2457(99)00322-3. [DOI] [PubMed] [Google Scholar]
  • 33.Dawson G, Klinger LG, Panagiotides H, Lewy A, Castelloe P. Subgroups of autistic children based on social behavior display distinct patterns of brain activity. J Abnorm Child Psychol. 1995;23(5):569–583. doi: 10.1007/BF01447662. [DOI] [PubMed] [Google Scholar]
  • 34.Stroganova TA, et al. Abnormal EEG lateralization in boys with autism. Clin Neurophysiol. 2007;118(8):1842–1854. doi: 10.1016/j.clinph.2007.05.005. [DOI] [PubMed] [Google Scholar]
  • 35.Zhang H, et al. Phosphoprotein analysis using antibodies broadly reactive against phosphorylated motifs. J Biol Chem. 2002;277(42):39379–39387. doi: 10.1074/jbc.M206399200. [DOI] [PubMed] [Google Scholar]
  • 36.Moritz A, et al. Akt-RSK-S6 kinase signaling networks activated by oncogenic receptor tyrosine kinases. Sci Signal. 2010;3(136):ra64. doi: 10.1126/scisignal.2000998. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Ricciardi S, et al. Reduced AKT/mTOR signaling and protein synthesis dysregulation in a Rett syndrome animal model. Hum Mol Genet. 2011;20(6):1182–1196. doi: 10.1093/hmg/ddq563. [DOI] [PubMed] [Google Scholar]
  • 38.Zhou J, Parada LF. PTEN signaling in autism spectrum disorders. Curr Opin Neurobiol. 2012;22:873–879. doi: 10.1016/j.conb.2012.05.004. [DOI] [PubMed] [Google Scholar]
  • 39.Bhaskar PT, Hay N. The two TORCs and Akt. Dev Cell. 2007;12(4):487–502. doi: 10.1016/j.devcel.2007.03.020. [DOI] [PubMed] [Google Scholar]
  • 40.Rosner M, Siegel N, Valli A, Fuchs C, Hengstschläger M. mTOR phosphorylated at S2448 binds to raptor and rictor. Amino Acids. 2010;38(1):223–228. doi: 10.1007/s00726-008-0230-7. [DOI] [PubMed] [Google Scholar]
  • 41.Willemsen MH, Rensen JHM, van Schrojenstein-Lantman de Valk HMJ, Hamel BCJ, Kleefstra T. Adult phenotypes in Angelman- and Rett-Like syndromes. Mol Syndromol. 2012;2(3-5):217–234. doi: 10.1159/000335661. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Foxe JJ, Snyder AC. The role of alpha-band brain oscillations as a sensory suppression mechanism during selective attention. Front Psychol. 2011;2:154. doi: 10.3389/fpsyg.2011.00154. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Uhlhaas PJ, Pipa G, Neuenschwander S, Wibral M, Singer W. A new look at gamma? High- (>60 Hz) γ-band activity in cortical networks: Function, mechanisms and impairment. Prog Biophys Mol Biol. 2011;105(1-2):14–28. doi: 10.1016/j.pbiomolbio.2010.10.004. [DOI] [PubMed] [Google Scholar]
  • 44.Palva S, Palva JM. New vistas for alpha-frequency band oscillations. Trends Neurosci. 2007;30(4):150–158. doi: 10.1016/j.tins.2007.02.001. [DOI] [PubMed] [Google Scholar]
  • 45.Ward LM. Synchronous neural oscillations and cognitive processes. Trends Cogn Sci. 2003;7(12):553–559. doi: 10.1016/j.tics.2003.10.012. [DOI] [PubMed] [Google Scholar]
  • 46.Buzsáki G. Theta rhythm of navigation: Link between path integration and landmark navigation, episodic and semantic memory. Hippocampus. 2005;15(7):827–840. doi: 10.1002/hipo.20113. [DOI] [PubMed] [Google Scholar]
  • 47.Jeste SS, Sahin M, Bolton P, Ploubidis GB, Humphrey A. Characterization of autism in young children with tuberous sclerosis complex. J Child Neurol. 2008;23(5):520–525. doi: 10.1177/0883073807309788. [DOI] [PubMed] [Google Scholar]
  • 48.Zoncu R, Efeyan A, Sabatini DM. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol. 2011;12(1):21–35. doi: 10.1038/nrm3025. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Peça J, et al. Shank3 mutant mice display autistic-like behaviours and striatal dysfunction. Nature. 2011;472(7344):437–442. doi: 10.1038/nature09965. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Chergui K, Svenningsson P, Greengard P. Physiological role for casein kinase 1 in glutamatergic synaptic transmission. J Neurosci. 2005;25(28):6601–6609. doi: 10.1523/JNEUROSCI.1082-05.2005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Viniegra JG, et al. Full activation of PKB/Akt in response to insulin or ionizing radiation is mediated through ATM. J Biol Chem. 2005;280(6):4029–4036. doi: 10.1074/jbc.M410344200. [DOI] [PubMed] [Google Scholar]
  • 52.Barlow C, et al. Atm-deficient mice: A paradigm of ataxia telangiectasia. Cell. 1996;86(1):159–171. doi: 10.1016/s0092-8674(00)80086-0. [DOI] [PubMed] [Google Scholar]
  • 53.Fehr S, et al. The CDKL5 disorder is an independent clinical entity associated with early-onset encephalopathy. Eur J Hum Genet. 2012 doi: 10.1038/ejhg.2012.156. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Neul JL, et al. RettSearch Consortium Rett syndrome: Revised diagnostic criteria and nomenclature. Ann Neurol. 2010;68(6):944–950. doi: 10.1002/ana.22124. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supporting Information

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

RESOURCES